vCJD transfusion-associated Fourth Case UK

My Photo
Name:
Location: BACLIFF, Texas, United States

My mother was murdered by what I call corporate and political homicide i.e. FOR PROFIT! she died from a rare phenotype of CJD i.e. the Heidenhain Variant of Creutzfeldt Jakob Disease i.e. sporadic, simply meaning from unknown route and source. I have simply been trying to validate her death DOD 12/14/97 with the truth. There is a route, and there is a source. There are many here in the USA. WE must make CJD and all human TSE, of all age groups 'reportable' Nationally and Internationally, with a written CJD questionnaire asking real questions pertaining to route and source of this agent. Friendly fire has the potential to play a huge role in the continued transmission of this agent via the medical, dental, and surgical arena. We must not flounder any longer. ...TSS

Friday, October 11, 2013

Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion

ORIGINAL ARTICLE

 

Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion

 

Nathalie Lescoutra-Etchegaray1,*, Chryslain Sumian2, Audrey Culeux1, Valérie Durand3, Patrick V. Gurgel4, Jean-Philippe Deslys3, Emmanuel E. Comoy3 Article first published online: 10 OCT 2013

 

DOI: 10.1111/trf.12420

 

© 2013 American Association of Blood Banks

 

 

 

Lescoutra-Etchegaray, N., Sumian, C., Culeux, A., Durand, V., Gurgel, P. V., Deslys, J.-P. and Comoy, E. E. (2013), Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion. Transfusion. doi: 10.1111/trf.12420

 

 Author Information 1 Macopharma, Fontenay-aux-Roses, France 2 Macopharma, Tourcoing, France 3 Institute of Emerging Diseases and Innovative Therapies (iMETI), Division of Prions and Related Diseases (SEPIA), CEA, Fontenay-aux-Roses, France 4 ProMetic Biosciences, Raleigh, North Carolina *Address reprint requests to: Nathalie Lescoutra-Etchegaray, Macopharma, 18 Route du Panorama, Bâtiment 60, 92265 Fontenay-aux-Roses, France; e-mail: nathalie.lescoutra@macopharma.com.

 

This work was supported by grants from Agence Nationale de la Recherche (ANR), Project PRIONSECUR ANR05PRIB02302.

 

Publication History Article first published online: 10 OCT 2013 Manuscript Accepted: 12 JUL 2013 Manuscript Revised: 10 JUL 2013 Manuscript Received: 23 APR 2013 Funded by Agence Nationale de la Recherche (ANR). Grant Number: PRIONSECUR ANR05PRIB02302

 

Background

 

 Five cases of variant Creutzfeldt-Jakob disease (vCJD) infections were attributed to infusion of contaminated blood components, turning to real the interhuman transmissibility of this prion disease from asymptomatic carriers. Preventive policies rely on exclusion from blood donation and benefit of leukoreduction initially implemented against leukotropic viruses. In the absence of available antemortem diagnostic tests, the updated prevalence of silent vCJD infections (1/2000 in the United Kingdom) urges the necessity to enforce blood safety with more efficient active measures able to remove the remaining infectivity.

 

Study Design and Methods Several affinity resins were demonstrated to reduce high levels of brain-spiked infectivity from human leukoreduced red blood cells (L-RBCs). One was integrated in a device adapted to field constraints (volumes, duration) of human transfusion. We assessed here the ability of the resulting removal filter, termed P-Capt, to remove infectivity from human L-RBC units spiked with scrapie-infected hamster brain (≥10,000 infectious units/mL), through inoculation of hamsters with pre- and post–blood filtration samples.

 

Results Incubation periods of recipient animals suggest around a 3-log removal of brain-derived prion infectivity by filtration through the P-Capt.

 

Conclusion On brain-derived spiked infectivity, the P-Capt filter provided a performance similar to the resin packed in columns used for initial proof-of-concept studies, suggesting an appropriate scale-up to efficiently remove infectivity from an individual human blood bag. According to the ability of resin to completely remove apparent endogenous infectivity from hamster leukoreduced blood, the implementation of such a filter, now commercially available, might seriously improve blood safety toward prions.

 


 

 

Sunday, September 29, 2013

 

Recalls raise questions on safety practices for donated blood CJD TSE PRION

 


 

 

 

Sent: Monday, October 07, 2013 9:54 PM

 


 

Subject: [CJD-L] Coexistence of Distinct Prion Types Enables Conformational Evolution of Human PrPSc by Competitive Selection

 


 

 

 

 

TSS